Controlling Shareholder of MedMira Announces Name Change and Addition of New Partners to Its Board

    




 HALIFAX, Sept. 26, 2012 /CNW/ - MedMira Inc., (MedMira) , a  developer of rapid diagnostic technology and solutions, announced today  that its largest and controlling shareholder, Andurja Beteiligungen AG  has changed its name to OnSite Lab Holding AG (OnSite Lab).  OnSite Lab  has further partnered with a Luxembourg-based investment fund,  Redalpine Capital II S.C.S., SICAR (Redalpine Capital), and a private  investment company, RLG APS, located in Copenhagen to enhance its Board  and investment focus in life science companies. 

 "The substantial investment we have made in MedMira represents our  strong commitment, our focus, and a key element of our strategic plan.  By changing our company's name to OnSite Lab Holding AG, we are moving  a step closer to building an even stronger affiliation with MedMira. We  are bringing the expertise of Redalpine and RLG APS on to our Board to  provide additional industry capabilities to MedMira.  Dr. Michael  Sidler, partner at Redalpine Capital, has a wealth of experience in the  life sciences and diagnostics industry and in linking science and  business entities.  RLG APS is led by Dr. H.P. Richard, a well  established Swiss medical doctor will offer further assistance to  MedMira for its expansion into new business opportunities and financing  networks. We are committed to work with the Company's management and  its Board to deliver the best value to all stakeholders of MedMira,"  said Urs Meile, Chairman of OnSite Lab Holding AG. 

 Meile continued, "Our investment in MedMira is a chance to be a part of  an evolutionary shift in the rapid diagnostics market.  We see MedMira  as an investment that not only covers the humanitarian side but it is  our strong belief that MedMira is one of the very few companies that  will yield a high return on investment in today's market." 

 "We are excited about the in-depth life sciences and diagnostics  industry knowledge, and business network brought by Dr. Sidler and Dr.  Richard through OnSite Lab.  We believe that their expertise will be  invaluable in optimizing MedMira's strategic direction during the next  phase of our growth," said Hermes Chan, CEO, MedMira Inc. 

 Dr. Sidler has been nominated as the board representative for OnSite Lab  on MedMira's Board of Directors.  This appointment is subject to final  approval of the TSX Venture Exchange. 

 About MedMira 

 MedMira is a leading developer and manufacturer of flow-through rapid  diagnostics and technologies. The Company's tests provide hospitals,  labs, clinics and individuals with reliable, rapid diagnosis for  diseases such as HIV and hepatitis C in just three minutes. The  company's tests are sold under the Reveal®, Multiplo™ and Miriad brands  in global markets. MedMira's rapid flow-through HIV test is the only  one in the world to achieve regulatory approvals in Canada, the United  States, China and the European Union. MedMira's corporate offices and  manufacturing facilities are located in Halifax, Nova Scotia, Canada.  For more information visit MedMira's website at www.medmira.com. 

 This news release contains forward-looking statements, including  statements relating to growth in the Company's business, earnings and  profitability, and trends in demand for the Company's products, which  involve risk and uncertainties and reflect the Company's current  expectation regarding future events including statements regarding  possible future growth and new business opportunities.  Actual events  could materially differ from those projected herein and depend on a  number of factors including, but not limited to, changing market  conditions, successful and timely completion of clinical studies,  uncertainties related to the regulatory approval process, establishment  of corporate alliances and other risks detailed from time to time in  the company quarterly filings. 

 Neither TSX Venture Exchange nor its Regulation Services Provider (as  that term is defined in the policies of the TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release. 

MEDMIRA INC.


CONTACT:  MedMira Contact:Andrea Young, Corporate CommunicationsTel: 902-450-1588Email: [e-mail] 


    

Copyright